相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
Bahareh Kashani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients
Maria A. Papadaki et al.
ANTICANCER RESEARCH (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Heterogeneity of Circulating Tumor Cell Neoplastic Subpopulations Outlined by Single-Cell Transcriptomics
Christine M. Pauken et al.
CANCERS (2021)
Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8
Anirban Roychowdhury et al.
GENE (2021)
A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
A. Farias et al.
SCIENTIFIC REPORTS (2021)
Systemic immunity in cancer
Kamir J. Hiam-Galvez et al.
NATURE REVIEWS CANCER (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Expression profile of Toll-like receptors in human breast cancer
Shuxun Shi et al.
MOLECULAR MEDICINE REPORTS (2020)
Role of STAT3 signaling pathway in breast cancer
Jia-hui Ma et al.
CELL COMMUNICATION AND SIGNALING (2020)
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
Xiaoming Zhong et al.
MOLECULAR CANCER (2020)
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
Maria A. Papadaki et al.
CANCERS (2020)
Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression
Fu Xiu-Qiong et al.
CELL DEATH & DISEASE (2020)
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
Breanna M. Allen et al.
NATURE MEDICINE (2020)
Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
Maria A. Papadaki et al.
CANCERS (2020)
STAT3 Differentially Regulates TLR4-Mediated Inflammatory Responses in Early or Late Phases
Akash Ahuja et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome
Hara Polioudaki et al.
CANCERS (2020)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Jiang-Jiang Qin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
STAT3, a Master Regulator of Anti-Tumor Immune Response
Cedric Rebe et al.
CANCERS (2019)
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Ioannis Zerdes et al.
CANCERS (2019)
Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis
Wenlong Ming et al.
FRONTIERS IN ONCOLOGY (2019)
511TiPA phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)
A R Hansen et al.
ANNALS OF ONCOLOGY (2019)
Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer
Maria A. Papadaki et al.
MOLECULAR CANCER THERAPEUTICS (2019)
The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer
Lorea Villanueva et al.
ONCOIMMUNOLOGY (2018)
Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells
Varun Sasidharan Nair et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Kumar Vijay
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer
Ippokratis Messaritakis et al.
PLOS ONE (2018)
Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis
Bo Hao et al.
Oncotarget (2018)
Signal Transducer and Activator of Transcription 3 Control of Human T and B Cell Responses
Elissa K. Deenick et al.
FRONTIERS IN IMMUNOLOGY (2018)
STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context
Ilenia Segatto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis
Renxu Chang et al.
NATURE COMMUNICATIONS (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
Survival Mechanisms and Influence Factors of Circulating Tumor Cells
Wen-Chao Wang et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
David M. Woods et al.
CLINICAL CANCER RESEARCH (2018)
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Lei Wang et al.
CANCER RESEARCH (2017)
STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC
L. L. Bu et al.
JOURNAL OF DENTAL RESEARCH (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells
Chun-Yu Liu et al.
MOLECULAR ONCOLOGY (2017)
The role of toll-like receptor 4 in tumor microenvironment
Jing Li et al.
ONCOTARGET (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Chunwan Lu et al.
ONCOIMMUNOLOGY (2017)
Constitutive activation of STAT3 in breast cancer cells: A review
Kasturi Banerjee et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
TLR4 Signaling via NANOG Cooperates With STAT3 to Activate Twist1 and Promote Formation of Tumor-Initiating Stem-Like Cells in Livers of Mice
Dinesh Babu Uthaya Kumar et al.
GASTROENTEROLOGY (2016)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
Galatea Kallergi et al.
BREAST CANCER RESEARCH (2015)
Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
Maria A. Papadaki et al.
BMC CANCER (2014)
Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells
Mark F. Santos et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
Prognostic Value of Myeloid Differentiation Primary Response 88 and Toll-Like Receptor 4 in Breast Cancer Patients
Fang-Jing Ma et al.
PLOS ONE (2014)
STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13
Huiyuan Zhang et al.
NATURE COMMUNICATIONS (2014)
Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling
Ilenia Segatto et al.
ONCOTARGET (2014)
Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
Yuting Ma et al.
IMMUNITY (2013)
TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer
Sandeep Rajput et al.
MOLECULAR CANCER THERAPEUTICS (2013)
IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3
Claire J. Greenhill et al.
JOURNAL OF IMMUNOLOGY (2011)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Toll-like Receptor 4 Signaling Promotes Tumor Growth
Che-Hsin Lee et al.
JOURNAL OF IMMUNOTHERAPY (2010)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Prognostic value of signal transducers and activators of transcription 3 in breast cancer
Shyr-Ming Sheen-Chen et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells
Yigang Qian et al.
CANCER INVESTIGATION (2008)
Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation:: Implications in graft-versus-host disease and antitumor immunity
Jean-Rene Pallandre et al.
JOURNAL OF IMMUNOLOGY (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Role of toll-like receptors in pathogen recognition
S Janssens et al.
CLINICAL MICROBIOLOGY REVIEWS (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
分享论文
